118 related articles for article (PubMed ID: 27685914)
1. Inhibitory effects of Silibinin combined with doxorubicin in hepatocellular carcinoma; an in vivo study.
Li WG; Wang HQ
J BUON; 2016; 21(4):917-924. PubMed ID: 27685914
[TBL] [Abstract][Full Text] [Related]
2. Silibinin strongly synergizes human prostate carcinoma DU145 cells to doxorubicin-induced growth Inhibition, G2-M arrest, and apoptosis.
Tyagi AK; Singh RP; Agarwal C; Chan DC; Agarwal R
Clin Cancer Res; 2002 Nov; 8(11):3512-9. PubMed ID: 12429642
[TBL] [Abstract][Full Text] [Related]
3. Silibinin efficacy against human hepatocellular carcinoma.
Varghese L; Agarwal C; Tyagi A; Singh RP; Agarwal R
Clin Cancer Res; 2005 Dec; 11(23):8441-8. PubMed ID: 16322307
[TBL] [Abstract][Full Text] [Related]
4. Silymarin and silibinin cause G1 and G2-M cell cycle arrest via distinct circuitries in human prostate cancer PC3 cells: a comparison of flavanone silibinin with flavanolignan mixture silymarin.
Deep G; Singh RP; Agarwal C; Kroll DJ; Agarwal R
Oncogene; 2006 Feb; 25(7):1053-69. PubMed ID: 16205633
[TBL] [Abstract][Full Text] [Related]
5. Silibinin upregulates the expression of cyclin-dependent kinase inhibitors and causes cell cycle arrest and apoptosis in human colon carcinoma HT-29 cells.
Agarwal C; Singh RP; Dhanalakshmi S; Tyagi AK; Tecklenburg M; Sclafani RA; Agarwal R
Oncogene; 2003 Nov; 22(51):8271-82. PubMed ID: 14614451
[TBL] [Abstract][Full Text] [Related]
6. Aspirin enhances doxorubicin-induced apoptosis and reduces tumor growth in human hepatocellular carcinoma cells in vitro and in vivo.
Hossain MA; Kim DH; Jang JY; Kang YJ; Yoon JH; Moon JO; Chung HY; Kim GY; Choi YH; Copple BL; Kim ND
Int J Oncol; 2012 May; 40(5):1636-42. PubMed ID: 22322725
[TBL] [Abstract][Full Text] [Related]
7. Oral silibinin inhibits lung tumor growth in athymic nude mice and forms a novel chemocombination with doxorubicin targeting nuclear factor kappaB-mediated inducible chemoresistance.
Singh RP; Mallikarjuna GU; Sharma G; Dhanalakshmi S; Tyagi AK; Chan DC; Agarwal C; Agarwal R
Clin Cancer Res; 2004 Dec; 10(24):8641-7. PubMed ID: 15623648
[TBL] [Abstract][Full Text] [Related]
8. Silibinin sensitizes human prostate carcinoma DU145 cells to cisplatin- and carboplatin-induced growth inhibition and apoptotic death.
Dhanalakshmi S; Agarwal P; Glode LM; Agarwal R
Int J Cancer; 2003 Sep; 106(5):699-705. PubMed ID: 12866029
[TBL] [Abstract][Full Text] [Related]
9. Dihydromyricetin suppresses the proliferation of hepatocellular carcinoma cells by inducing G2/M arrest through the Chk1/Chk2/Cdc25C pathway.
Huang H; Hu M; Zhao R; Li P; Li M
Oncol Rep; 2013 Nov; 30(5):2467-75. PubMed ID: 24002546
[TBL] [Abstract][Full Text] [Related]
10. WP1130 increases doxorubicin sensitivity in hepatocellular carcinoma cells through usp9x-dependent p53 degradation.
Liu H; Chen W; Liang C; Chen BW; Zhi X; Zhang S; Zheng X; Bai X; Liang T
Cancer Lett; 2015 Jun; 361(2):218-25. PubMed ID: 25749422
[TBL] [Abstract][Full Text] [Related]
11. Effects of silymarin and silymarin-doxorubicin applications on telomerase activity of human hepatocellular carcinoma cell line HepG2.
Yurtcu E; Darcansoy Iseri O; Iffet Sahin F
J BUON; 2015; 20(2):555-61. PubMed ID: 26011349
[TBL] [Abstract][Full Text] [Related]
12. Strategy to enhance the therapeutic effect of doxorubicin in human hepatocellular carcinoma by selenocystine, a synergistic agent that regulates the ROS-mediated signaling.
Fan C; Zheng W; Fu X; Li X; Wong YS; Chen T
Oncotarget; 2014 May; 5(9):2853-63. PubMed ID: 24797310
[TBL] [Abstract][Full Text] [Related]
13. Synergistic anti-tumor efficacy of doxorubicin and flavopiridol in an in vivo hepatocellular carcinoma model.
Kwak MS; Yu SJ; Yoon JH; Lee SH; Lee SM; Lee JH; Kim YJ; Lee HS; Kim CY
J Cancer Res Clin Oncol; 2015 Nov; 141(11):2037-45. PubMed ID: 25989942
[TBL] [Abstract][Full Text] [Related]
14. Shufeng Jiedu Capsule and its active ingredients induce apoptosis, inhibit migration and invasion, and enhances doxorubicin therapeutic efficacy in hepatocellular carcinoma.
Xia J; Rong L; Sawakami T; Inagaki Y; Song P; Hasegawa K; Sakamoto Y; Tang W
Biomed Pharmacother; 2018 Mar; 99():921-930. PubMed ID: 29710492
[TBL] [Abstract][Full Text] [Related]
15. Inhibitory effect of oleanolic acid on hepatocellular carcinoma via ERK-p53-mediated cell cycle arrest and mitochondrial-dependent apoptosis.
Wang X; Bai H; Zhang X; Liu J; Cao P; Liao N; Zhang W; Wang Z; Hai C
Carcinogenesis; 2013 Jun; 34(6):1323-30. PubMed ID: 23404993
[TBL] [Abstract][Full Text] [Related]
16. Combined treatment with silibinin and either sorafenib or gefitinib enhances their growth-inhibiting effects in hepatocellular carcinoma cells.
Gu HR; Park SC; Choi SJ; Lee JC; Kim YC; Han CJ; Kim J; Yang KY; Kim YJ; Noh GY; No SH; Jeong JH
Clin Mol Hepatol; 2015 Mar; 21(1):49-59. PubMed ID: 25834802
[TBL] [Abstract][Full Text] [Related]
17. Bufotalin from Venenum Bufonis inhibits growth of multidrug resistant HepG2 cells through G2/M cell cycle arrest and apoptosis.
Zhang DM; Liu JS; Tang MK; Yiu A; Cao HH; Jiang L; Chan JY; Tian HY; Fung KP; Ye WC
Eur J Pharmacol; 2012 Oct; 692(1-3):19-28. PubMed ID: 22841670
[TBL] [Abstract][Full Text] [Related]
18. Chk1 and Wee1 control genotoxic-stress induced G2-M arrest in melanoma cells.
Vera J; Raatz Y; Wolkenhauer O; Kottek T; Bhattacharya A; Simon JC; Kunz M
Cell Signal; 2015 May; 27(5):951-60. PubMed ID: 25683911
[TBL] [Abstract][Full Text] [Related]
19. Norcantharidin combined with ABT-737 for hepatocellular carcinoma: Therapeutic effects and molecular mechanisms.
Ren J; Li G; Zhao W; Lin L; Ye T
World J Gastroenterol; 2016 Apr; 22(15):3962-8. PubMed ID: 27099439
[TBL] [Abstract][Full Text] [Related]
20. Hyperthermia enhances 17-DMAG efficacy in hepatocellular carcinoma cells with aggravated DNA damage and impaired G2/M transition.
Huang Z; Zhou X; He Y; Ke X; Wen Y; Zou F; Chen X
Sci Rep; 2016 Dec; 6():38072. PubMed ID: 27909289
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
